Literature DB >> 34114417

Stevens-Johnson syndrome/toxic epidermal necrolysis induced by pirfenidone.

Dario de Perosanz-Lobo1, D Fernández-Nieto1, P Burgos-Blasco1, M Aroca-Ruiz2, M Fernández-Guarino1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34114417     DOI： 10.25259/IJDVL_61_20

Source DB:  PubMed          Journal:  Indian J Dermatol Venereol Leprol        ISSN： 0378-6323            Impact factor:   2.545


× No keyword cloud information.
  3 in total

1.  Randomized, controlled trial of TNF-α antagonist in CTL-mediated severe cutaneous adverse reactions.

Authors:  Chuang-Wei Wang; Lan-Yan Yang; Chun-Bing Chen; Hsin-Chun Ho; Shuen-Iu Hung; Chih-Hsun Yang; Chee-Jen Chang; Shih-Chi Su; Rosaline Chung-Yee Hui; See-Wen Chin; Li-Fang Huang; Yang Yu-Wei Lin; Wei-Yang Chang; Wen-Lang Fan; Chin-Yi Yang; Ji-Chen Ho; Ya-Ching Chang; Chun-Wei Lu; Wen-Hung Chung
Journal:  J Clin Invest       Date:  2018-02-05       Impact factor: 14.808

2.  An Open-Label Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (RECAP).

Authors:  Ulrich Costabel; Carlo Albera; Lisa H Lancaster; Chin-Yu Lin; Philip Hormel; Henry N Hulter; Paul W Noble
Journal:  Respiration       Date:  2017-09-13       Impact factor: 3.580

3.  Long-term safety of pirfenidone: results of the prospective, observational PASSPORT study.

Authors:  Vincent Cottin; Dirk Koschel; Andreas Günther; Carlo Albera; Arata Azuma; C Magnus Sköld; Sara Tomassetti; Philip Hormel; John L Stauffer; Indiana Strombom; Klaus-Uwe Kirchgaessler; Toby M Maher
Journal:  ERJ Open Res       Date:  2018-10-19
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.